Home/MapLight Therapeutics/David L. Gray, Ph.D.
DL

David L. Gray, Ph.D.

Chief Scientific Officer

MapLight Therapeutics

MapLight Therapeutics Pipeline

DrugIndicationPhase
ML-007Social impairment in Autism Spectrum DisorderPhase 2
ML-104Treatment-resistant DepressionPreclinical
ML-225Cognitive impairment in Alzheimer's DiseasePreclinical
Undisclosed ProgramAnxiety DisordersDiscovery